we identified novel ADAR and RNASEH2B variants, and a 3-to 17-fold frequency increase of the AGS mutations ADAR,c.577C>G;p.(P193A) and RNASEH2B,c.529G>A;p. (A177T) in the germline of familial glioma patients as well as in test and validation cohorts of glioblastomas and prostate carcinomas versus ethnicity-matched controls, whereby rare RNASEH2B variants were significantly more frequent in familial glioma patients. Tumors with ADAR or RNASEH2B variants recapitulated features of AGS, such as calcification and increased type I interferon expression. Patients carrying ADAR or RNASEH2B variants showed upregulation of interferon-stimulated gene (ISG) transcripts in peripheral blood as seen in AGS. An increased ISG expression was also induced by ADAR and RNASEH2B variants in tumor cells and was blocked by the JAK inhibitor Ruxolitinib. Our data implicate rare variants in the AGS genes ADAR and RNASEH2B and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis, consistent with a genetic basis underlying inflammation-driven Abstract In search of novel germline alterations predisposing to tumors, in particular to gliomas, we studied a family with two brothers affected by anaplastic gliomas, and their father and paternal great-uncle diagnosed with prostate carcinoma. In this family, whole-exome sequencing yielded rare, simultaneously heterozygous variants in the Aicardi-Goutières syndrome (AGS) genes ADAR and RNASEH2B co-segregating with the tumor phenotype. AGS is a genetically induced inflammatory disease particularly of the brain, which has not been associated with a consistently increased cancer risk to date. By targeted sequencing, 
Introduction
Diffuse gliomas are brain tumors classified by the World Health Organisation (WHO) according to their malignancy, encompassing astrocytomas and oligodendrogliomas of grade II or III, and glioblastomas classified as most malignant grade IV. Most cases of diffuse glioma, as well as of prostate carcinoma occur sporadically. However, familial aggregation of gliomas does exist, accounting for around 5% of patients according to Malmer et al. [43] . In addition, glioma susceptibility is increased in patients suffering from certain inherited cancer syndromes, such as neurofibromatosis type 1 and 2, Li-Fraumeni syndrome, and brain tumor polyposis syndromes 1 (Turcot) and 2 (Gardner) (reviewed in [36] ), suggesting that genetic alterations play a role in glioma risk. Similarly, familial prostate cancer has been described and tumor syndromes exist that are associated with prostate cancer susceptibility, e.g., Lynch syndrome and hereditary breast and ovarian cancer caused by mutations in DNA-repair genes (reviewed in [41] ). Interestingly, genetic alterations in certain genes (e.g., the mismatch repair genes MSH2, MSH6, MLH1, and PMS2) or chromosomal regions (e.g., the 8q24 locus) confer increased risk for different tumor entities including gliomas [35, 36] and prostate cancer [4, 41] . Therefore, in some families, gliomas and prostate cancer may both be part of a tumor spectrum associated with a common genetic basis. Screening these families for tumor predisposing germline alterations may allow identification of novel genes increasing the risk for these tumor entities, which may also be relevant for sporadic tumor patients. As next-generation sequencing technologies have been instrumental in identifying new tumor predisposing genes, such as POT1 [5] in familial gliomas, we performed whole-exome sequencing in a family with gliomas and prostate carcinomas in four individuals from three consecutive generations. In all affected individuals analyzed, an overlapping data analysis strategy yielded rare, simultaneously heterozygous variants in ADAR and RNASEH2B, two genes mutated in Aicardi-Goutières syndrome (AGS).
AGS was first described as an infancy onset and rapidly progressive encephalopathy with basal ganglia calcifications and lymphocytosis in the cerebrospinal fluid, reminiscent of an inflammatory process [2] . Presently, AGS is known to be a genetic disorder inherited in an autosomal recessive manner in most cases, and is referred to as a type I interferonopathy because of a constitutive upregulation of type I interferon (IFN) signaling (reviewed in [18] ). The genetic cause of AGS is a mutation in one of seven genes, which encode the three subunits of the ribonuclease H2 (RNase H2) endonuclease complex, RNASEH2A, RNASEH2B, and RNASEH2C [17] , the 3′-5′ DNA exonuclease TREX1 [16] , the deoxynucleoside triphosphate triphosphohydrolase and putative exonuclease SAMHD1 [58] , the adenosine deaminase acting on RNA ADAR [60] , or the cytosolic doublestranded RNA (dsRNA) receptor IFIH1 [59] . ADAR is a dsRNA-editing enzyme that catalyzes the conversion of adenosine to inosine mainly in transcripts expressed in the central nervous system (CNS) [32] , and it is an essential suppressor of interferon signaling [27] . RNase H2 cleaves the RNA strand of cellular RNA:DNA hybrids and hydrolyzes ribonucleotides misincorporated into DNA (reviewed in [55] ). It is essential for genome stability and mouse embryonic development, with widespread DNA damage observed in RNase H2 null cells [30, 56] . RNase H2 deficiency is thought to cause accumulation of cytoplasmic DNA or RNA:DNA resulting from genome instability or endogenous retroviruses, which activate the cGAS-STING innate immune pathway [42, 53] .
More generally, accumulation of unprocessed self nucleic acids and subsequent activation of type I IFN signaling are thought to underlie AGS disease pathogenesis. Clinical features include an IFN-stimulated gene (ISG) expression signature as well as inflammation, calcification, and neurodegeneration (reviewed in [31] ). However, there have also been suggestions that AGS gene variation may be associated with tumorigenesis. Altered ADAR-mediated A-to-I RNA editing was detected in human cancer, whereby global hypoediting 1 3 described in brain and prostate tumors [50] may be involved in the dedifferentiation of glioma cells [34] . Loss of RNase H2 function was shown to lead to large-scale genomic instability [56] , which may be relevant for tumorigenesis. More evidence for an association of AGS and tumor risk comes from an AGS patient carrying a SAMHD1 germline mutation who developed chronic lymphocytic leukemia (CLL) at 24 years of age [14] . In addition, somatic SAMHD1 variants were found in around 10% of relapsed or refractory patients with CLL [14] .
In the present study, we present data suggesting that rare partial loss-of-function variants affecting AGS-associated genes ADAR and RNASEH2B increase the risk for glioma and prostate carcinoma. Glioma patients carrying ADAR and/or RNASEH2B mutations and their tumors show signs of a type I interferonopathy. In summary, our data suggest a genetic link between inflammatory processes and the development of glioma and prostate carcinoma.
Materials and methods

Human samples
For the familial glioma cohort (n = 60, of these 33 patients were diagnosed with glioblastoma of WHO grade IV), blood samples were collected from glioma patients with evidence for a genetic tumor predisposition because of multiple successive tumors in the glioma patient or tumors in the family history, mainly in Hannover, Lower Saxony, Germany. This cohort includes families 1 and 2. From patient II.2 of family 2, a skin biopsy was performed to obtain fibroblasts. Control fibroblasts were derived from four sex-matched individuals. For the non-familial glioma cohort (n = 50, of these 41 patients were diagnosed with glioblastoma), blood samples were collected from glioma patients without multiple successive tumors or family history of tumors in Hannover, Germany. Blood samples from 130 glioma patients diagnosed with IDH1-mutant gliomas of WHO grades II or III had been collected in multiple German centers excluding Hannover, and were retrieved from the archives of the German Glioma Network (GGN) (www.gliomnetzwerk.de) [54, 65] , which was supported by the German Cancer Aid from 2004 to 2012. Formalin-fixed paraffin-embedded (FFPE) samples from 39 gliomas of WHO grades II or III shown to be IDH1-mutant and from 20 glioblastomas (test cohort) were retrieved from the archives of the Division of Neuropathology, Hannover Medical School, Hannover, Germany. The glioblastoma test cohort includes patient II.1 of family 3, whose RNASEH2B variant was also detected in nonneoplastic tissue representing the germline. DNA from 56 glioblastomas (validation cohort) was retrieved from the GGN archives. DNA from 15 FFPE prostate carcinoma samples (test cohort) was retrieved from the archives of the Institute of Pathology, Hannover Medical School, Hannover, Germany. The prostate carcinoma test cohort includes patients II.1 of families 4 and 5, whose ADAR or RNASEH2B variants were also detected in non-neoplastic lymph node representing the germline. FFPE samples from 50 prostate carcinomas (validation cohort) were retrieved from the archives of the Institute of Pathology, University of Rostock, Rostock, Mecklenburg-Western Pomerania, Germany. All patients provided written informed consent for the use of their tissue samples for research purposes. The study was approved by the Ethics Board of Hannover Medical School, Hannover, Germany, and of the University of Tübingen, Germany.
Whole-exome sequencing (WES)
WES on whole blood DNA from three cancer-affected members of family 1 (patients II.2, III.2, and III.3), and on tumor DNA from the anaplastic glioma of patient III.3 of family 1 was done using the Agilent SureSelectXT All Exon V4 (blood and tumor DNA from patients III.2 and III.3) or V5 (blood DNA from patient II.2) target enrichment kits on an Illumina HiSeq 2000 by Oxford Gene Technology (OGT) [13] . All samples were sequenced to a mean target coverage of > 50×. More specifically, on whole blood DNA from patients II.2, III.2, and III.3, average coverage of the ADAR coding region was 62×, 96×, and 79× whereby 91, 88, and 86% were covered at > 25×, while average coverage of the RNASEH2B coding region was 60×, 52×, and 39× whereby 77, 82, and 66% were covered at > 25×. WES germline data were analyzed using INGENUITY Variant Analysis™ (INGENUITY Systems, QIAGEN, Redwood City, USA) and our in-house NGS data analysis workflow as described in Results and Supplementary Tables 1-4 . For prediction of variant deleteriousness, the tools SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), MutationTaster (http://www.mutationtaster.org), and PROVEAN (http://provean.jcvi.org) were used. Minor allele frequency (MAF) in the European population (non-Finnish) was retrieved from the Exome Aggregation Consortium (ExAC) Browser Beta [39] . Variant verification and co-segregation analysis in families 1 and 2 were done using conventional chain termination protocols on a 3130XL Genetic Analyzer (Applied Biosystems, Darmstadt, Germany). Nucleotide numbering of the identified variants reflects complementary DNA (cDNA) numbering in the GenBank reference sequence. WES tumor data of patient III.3 of family 1 were analyzed with respect to single-nucleotide variants and copy number variants within the ADAR and RNASEH2B loci.
Sequence analysis of ADAR, RNASEH2B, and SNP rs498872 at 11q23
Whole blood genomic DNA was isolated using QIAamp blood DNA kits (Qiagen, Hilden, Germany). Phenol-chloroform extraction was used to isolate tumor DNA from FFPE tissue. Coding sequences of interferon-induced ADAR isoform p150 (NG_011844, NM_001111) or RNASEH2B (NG_009055, NM_024570) were amplified using oligonucleotides binding to sequences in close proximity to exon-intron boundaries (Supplementary Tables 5, 6 ). Using conventional chain termination protocols on a 3130XL Genetic Analyzer, (1) the entire coding regions including splice sites of ADAR and RNASEH2B were screened for germline mutations in familial glioma patients and patients with IDH1-mutant WHO grade II/III gliomas, (2) the entire coding region including splice sites of RNASEH2B as well as ADAR exons 2, 5, 8, and 11 were screened for mutations in IDH1-mutant gliomas of WHO grade II/III and the glioblastoma and prostate carcinoma test cohorts, (3) hot spot exons, i.e., ADAR: exons 2, 5, 8, and 11; RNASEH2B: exons 6 and 7, were screened for germline mutations in non-familial glioma patients, and for mutations in the glioblastoma and prostate carcinoma validation cohorts. Genotyping of SNP rs498872 (NM_015157.3:c.-199A>G) located in the 5′ UTR of the PHLDB1 gene at 11q23 was done on germline DNA from patients II.2, III.2, and III.3 of family 1, and patient II.2 of family 2 using conventional chain termination protocols.
Molecular characterization of gliomas
To determine the IDH1 mutational status, tumor DNA was analyzed using Sanger sequencing or pyrosequencing, or immunohistochemistry using an antibody specifically recognizing the IDH1-R132H mutation was performed on tissue sections [9, 21, 26] . O 6 -methylguanine DNA methyltransferase (MGMT) promoter methylation was assessed by methylation-specific polymerase chain reaction or pyrosequencing on glioma DNA [20] . The presence or absence of 1p/19q co-deletion was determined by fluorescence in situ hybridization using 1p-and 19q-specific probes on tissue sections or array-CGH on glioma DNA.
Molecular dynamics (MD) simulations
All MD simulations were carried out using NAMD 2.11 [52] and the CHARMM36 force field [7, 25] . Starting coordinates for the duplex Z-DNA-ADAR Zα complex were taken from the crystal structure of human Zα domain with bound Z-DNA (PDB code: 1QBJ). Simulations were performed in explicit solvent using the TIP3P water model [37] , and the total charge of each system was neutralized by adding Na + counter ions. Each system was initially energy-minimized and subsequently equilibrated for at least 5 ns. MD production runs of each system were conducted for 100 ns at the Computer Cluster of the Norddeutscher Verbund für Hochund Höchstleistungsrechnen with periodic boundary conditions in the NpT ensemble at a constant temperature (310 K) and constant pressure (1 atm). A 12 Å cutoff was used for non-bonded short-range interactions and the particle-mesh Ewald method [19] for long-range electrostatics.
Cloning of expression constructs
Human expression constructs pCMV-HA-ADAR p150 (Yanick Crow, University of Manchester, U.K.) and pcDNA3.1-RNASEH2B-Myc/His were described elsewhere [17, 60] . Their ORFs were subcloned into pIRESneo (Matthias Dobbelstein, University of Göttingen, Germany). Murine Rnaseh2b ORF was subcloned into pcDNA3. 
Tp53
−/− mouse embryonic fibroblasts (MEFs) [56] , and skin biopsy derived primary human fibroblasts were cultured in DMEM (Merck Millipore, Billerica, MA, USA) supplemented with 10% fetal bovine serum, 2 mM l-glutamine, and 1% penicillin/streptomycin (all Thermo Fisher Scientific). For HCT116 cells, RPMI 1640 (Merck Millipore) was used. Transient transfection was done using Lipofectamine 3000 reagent (Thermo Fisher Scientific). Stably transfected cell lines were generated by incubation in growth medium supplemented with 600 µg/ ml geneticin (Thermo Fisher Scientific) for at least 20 days. Stable ADAR expression was verified by PCR amplification of ADAR wild-type/mutant inserts using oligonucleotides specifically binding to ADAR cDNA sequences. To inhibit JAK1/2 kinases and subsequent JAK/STAT signaling, LN-229 cells were treated with 1 µM of the JAK inhibitor Ruxolitinib dissolved in DMSO versus DMSO control (Selleck Chemicals, Suffolk, UK) for 44 h.
Cell proliferation assay
Stably transfected LN-229 or HCT116 cells were seeded in triplicate at a density of 100,000 or 150,000 cells. Cells were counted 9-12 times using the Scepter™ counter (Merck Millipore), and were re-seeded after counting. Growth kinetics were determined for 27 or 28 days, and specific growth rates were calculated. The experiment was repeated once.
Detection of ribonucleotides in genomic DNA
Rnaseh2b
+/+ ; Tp53 −/− , Rnaseh2b +/− ; Tp53 −/− , and Rnaseh2b −/− ; Tp53 −/− MEFs [56] were transiently transfected with Rnaseh2b constructs or empty vector and cultured for 48 h. MEFs were mechanically disrupted in icecold lysis buffer (20 mM Tris-HCl, pH 7.5, 75 mM NaCl, 50 mM EDTA), incubated with 100 µg/ml proteinase K, and completely lysed using sodium dodecyl sulphate at a final concentration of 1%. Nucleic acids were sequentially extracted with TE-equilibrated phenol, phenol:chlorofor m:isoamylalcohol (25:24:1), and chloroform, precipitated with isopropanol, washed with 75% ethanol, and dissolved in water over night at 4 °C. Digestion with RNase HII (NEB, Frankfurt am Main, Germany) was carried out for 1 h at 37 °C, and nucleic acids were ethanol precipitated and dissolved in water. For alkaline gel electrophoresis [48] , one volume of loading buffer (300 mM NaOH, 6 mM EDTA, 7.5% Ficoll (Type 400), 0.35% Orange G) was added to each sample, and DNA was separated on a 0.5% agarose gel (50 mM NaCl, 1 mM EDTA) using an alkaline running buffer (50 mM NaOH, 1 mM NaCl) for 16 h at 16 V (B1 mini-gel format; Thermo Fisher Scientific). After electrophoresis, gels were neutralized with 0.7 M Tris/HCl buffer (pH 8.0) containing 1.5 M NaCl for 1 h at RT and stained with SYBR Gold for 1 h at RT (1:10,000 dilution; Thermo Fisher Scientific).
Immunofluorescence staining
Rnaseh2b
−/− ; Tp53 −/− MEFs transiently transfected with myc-tagged Rnaseh2b constructs or vector control expressing RFP, and fibroblasts from patient II.2 of family 2 and controls were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100, and probed with rabbit antiphospho-histone H2AX Ser139 (1:400, #2577, Cell Signaling Technologies, Danvers, MA, USA). The secondary goat anti-rabbit antibody was Alexa Fluor 488-conjugated (1:500 dilution, A11034, Thermo Fisher Scientific). Transfected MEFs were visualized by co-immunostaining using mouse anti-myc (1:200 dilution, sc-40, Santa Cruz Biotechnology, Dallas, TX, USA) and Alexa Fluor 568-conjugated goat antimouse antibody (1:500 dilution, A10037, Thermo Fisher Scientific). Vector control transfected cells were detected by RFP fluorescence. Cell nuclei were counterstained with DAPI, and analyzed using an epifluorescence microscope (CW4000, Leica Microsystems, Wetzlar, Germany). Cells with more than 5 strong nuclear γH2AX-foci were counted in 100 randomly selected transfected Rnaseh2b −/− MEFs [56] . For each patient or control, the number of fibroblasts harboring 0-3 nuclear DNA γH2AX-foci was determined in 50 randomly selected cells (nuclei with more than 3 stress foci were excluded) [23] .
LN-229 cells transiently transfected with ADAR or RNASEH2B expression constructs and co-transfected with pEGFP-C1 were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100, stained with rabbit anti-IRF3 antibody (1:200 dilution, FL-425, Santa Cruz Biotechnology), and an Alexa Fluor 568-conjugated goat anti-rabbit IgG (1:500 dilution; A11011; Thermo Fisher Scientific). For each transfected sample, 200 GFP-positive cells were evaluated semi-quantitatively for their nuclear IRF3 expression level by taking into account the average staining intensity of each visual field and using the scores: 0; no; 1, weak; 2, moderate; 3, strong.
The co-expression of IFNA6 and GFAP as well as CXCL10 and GFAP was assessed on FFPE glioma sections of patient III.3 of family 1 after heat-induced epitope retrieval in 10 mM citrate buffer pH 6.0, using rabbit anti-IFNA6 (1:100 dilution, HPA047557, Atlas Antibodies) or rabbit anti-CXCL10 (1:100 dilution, bs-1502R, bioss Center for Biological Signalling Studies, University of Freiburg, Germany), and co-staining with mouse anti-GFAP (1:100 dilution, M0761, Dako, Glostrup, Denmark) as primary antibodies. As secondary antibodies, Alexa Fluor 568-conjugated donkey anti-rabbit IgG (1:300 dilution, A10042, Thermo Fisher Scientific) and DyLight 488-conjugated goat anti-mouse IgG (1:300 dilution, #35503, Thermo Fisher Scientific) were used. Cell nuclei were stained using Hoechst 33342 (Thermo Fisher Scientific).
Assessment of calcification in tissue sections
FFPE glioma and prostate carcinoma sections were hematoxylin-eosin (HE) or von Kossa stained and evaluated for visible calcifications using the following score: 1, no detected calcification; 2, one small calcification; 3, several small calcifications; 4, several large calcifications.
Expression analysis of IFNA6, CXCL10, and CD68 by immunohistochemistry
The expression of IFNA6, CXCL10, and CD68 was assessed on FFPE glioma sections after heat-induced epitope retrieval in 10 mM citrate buffer pH 6.0, using rabbit anti-IFNA6 (1:100 dilution, HPA047557, Atlas Antibodies), rabbit anti-CXCL10 (1:300 dilution, bs-1502R, bioss Center for Biological Signalling Studies, University of Freiburg, Germany), and mouse anti-CD68 (1:200 dilution, M 0876, Dako) as primary antibodies. To improve CXCL10 staining, the antibody was diluted in Pierce immunostain enhancer (Thermo Fisher Scientific). As secondary antibody, horseradish-peroxidase-labeled goat anti-rabbit IgG (1:200 dilution, A24537, Thermo Fisher Scientific) was used. Sections were counterstained with hematoxylin (Gill No. 3, 1:10 dilution), scanned using the Aperio AT2 Scanner (Leica Microsystems), and digital images were processed using ImageScope v11.2.0.780 software (Leica Microsystems). On digital images of glioma sections from six patients with and five patients without rare ADAR or RNASEH2B variants, staining was assessed in six stained, non-overlapping, and non-necrotic areas per section using the following scoring system for staining intensity per area: 0.5, very weak; 1.0, weak; 1.5, moderate; 2.0, moderate to strong; 2.5, strong; 3.0, very strong, and mean staining intensity was calculated for each section.
Expression analysis of interferon-stimulated genes (ISG) by real time RT-PCR
The expression of six ISGs, found to be significantly upregulated in AGS patients [60] , was assessed in whole blood of male patients III.2 and III.3 of family 1, female patient II.2 of family 2, and 20 controls (10 female and 10 male) matching the sex and age of the three glioma patients. Total RNA was extracted using the PAXgene RNA isolation kit (PreAnalytix, Hombrechtikon, Switzerland). The expression of the three genes found to be upregulated in glioma patients (patients III.2 and III.3 of family 1, patient II.2 of family 2) was assessed in transiently transfected LN-229 cells that had been treated with 1 µM Ruxolitinib in DMSO or DMSO control. Total RNA was extracted using the RNeasy Mini Kit (Qiagen). cDNA was generated using the Superscript III First-Strand Synthesis System (Thermo Fisher Scientific). Relative quantification was performed using TaqMan Universal PCR Master Mix and TaqMan probes for IFI27 (Hs01086370_m1), IFI44L (Hs00199115_ m1), IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_ m1) (all Thermo Fisher Scientific). Target gene expression levels were normalized to the expression levels of 18S (Hs999999001_s1) and HPRT1 (Hs03929096_g1), and comparative C t quantification was applied. Comparisons between expression levels of the six genes in the patient and the control group were calculated using two-tailed Student's t test; multiple testing was corrected for using the Bonferroni-type False Discovery Rate procedure according to Benjamini and Hochberg [6] .
Statistics
Data are presented as mean ± SD. Statistical significance was calculated using two-tailed Student's t test or Chi-square test, and statistically significant p values are indicated. (Fig. 1a) , and WES was performed. First, to identify variants associated with glioma risk, germline variants shared by the two brothers were analyzed using an overlapping strategy (Supplementary Table 1 ). Of the shared high-quality variants, 108 were rare (MAF < 1%), non-silent (i.e., non-synonymous missense, non-sense, frameshift, and splice site variants), and not found in 56 unrelated in-house controls. Of these variants, 28 fulfilled the following additional criteria: (1) predicted to be deleterious by at least one of four prediction tools, (2) located within protein domains according to the Uniprot catalog, and (3) affected genes harbor a second hit (singlenucleotide or copy number variant) in the glioma DNA of patient III.3 based on WES data (Supplementary Table 2 ). A second filtering strategy was applied to the WES data, based on the hypothesis that the prostate carcinomas and the IDH1-mutant anaplastic astrocytomas in family 1 were part of a cancer syndrome caused by the same genetic variants. Therefore, germline variants shared by patients II.2, III.2, and III.3 were determined (Supplementary Table 3 ). Of the shared high-quality variants, 44 were rare (MAF < 1%), non-silent (i.e., non-synonymous missense, non-sense, frameshift, and splice site variants), and not found in 56 unrelated in-house controls. Of these variants, nine fulfilled the following additional criteria: (1) predicted to be deleterious by at least one of four prediction tools, (2) located within protein domains according to the Uniprot catalog, and (3) affected genes harbor a second hit (single-nucleotide or copy number variant) in the glioma DNA of patient III.3 based on WES data (Supplementary Table 4 ). Manual curation of the 28 variants potentially associated with glioma risk (Supplementary  Table 2 ), and the nine variants potentially associated with glioma/prostate carcinoma risk (Supplementary Table 4) by a clinical geneticist (RGW) yielded two heterozygous variants in genes associated with the same rare autosomal recessive genetic disorder, AGS: ADAR,c.577C>G;p. (P193A), a mutation previously described in AGS patients [60] , and RNASEH2B,c.495G>T;p.(K165N), a novel missense variant in the AGS gene RNASEH2B [17] (Supplementary Tables 9, 10 ). Verification and segregation analysis by Sanger sequencing in family 1 revealed that only the three family members affected by tumors and from whom DNA was available were simultaneously heterozygous for these ADAR and RNASEH2B variants, while three cancer-unaffected family members were not ( Fig. 1a; Supplementary  Fig. 1a ). Through WES analysis of DNA derived from the IDH1-mutant anaplastic astrocytoma of patient III.3, second hits were detected in the ADAR and RNASEH2B genes, in addition to the germline missense variants, i.e., a 143 bp deletion partially affecting ADAR exon 3, a 286 bp deletion affecting ADAR exon 14, and a 225 bp deletion partially affecting RNASEH2B exon 1. Tumor DNA from the other two cancer-affected members of family 1 was not available for genetic analysis.
Results
Rare variants in the AGS
We then determined whether germline variants in ADAR and RNASEH2B occur at higher than normal frequencies in glioma patients with evidence for a genetic tumor predisposition, either because of multiple successive tumors in the glioma patient or cancer in family members, for whom we use the term familial glioma patients. Targeted sequencing of both genes on germline DNA of 59 additional familial glioma patients was performed. We detected that glioblastoma patient II.2 of family 2 was heterozygous for RNASEH2B,c.529G>A;p.(A177T) (Fig. 1b; Supplementary  Fig. 1b; Supplementary Tables 9, 10 ), a variant previously described in AGS patients [17] , although the presence of two non-affected heterozygous mutation carriers in family 2 indicates incomplete penetrance for a tumor phenotype (Fig. 1b ; (A177T) (M3), two known AGS mutations, were also detected in the germline (non-neoplastic tissue) and tumor of glioblastoma patients in families 3 and 4 as well as in the germline (non-neoplastic tissue) and tumor of prostate carcinoma patients in families 5 and 6. Question marks indicate that it is unknown whether an individual was affected by a tumor or not Supplementary Fig. 1b) . However, the allele frequency for both of the AGS-associated variants ADAR,c.577C>G;p. (P193A) and RNASEH2B,c.529G>A;p.(A177T) was 0.00833 (1 in 120 alleles) in familial glioma patients and, therefore, around 3 and 4 times higher than in non-Finnish Europeans from the ExAC data set [39] , i.e., 0.00298 (199 in 66740 alleles) and 0.00193 (128 in 66494 alleles), respectively, and both variants were not found in 263 in-house control exomes. In addition, a novel RNASEH2B variant was detected (Supplementary Table 9 ). Taken together, the frequency of all rare (MAF < 1%) non-silent deleterious RNASEH2B variants (that is, frameshift, stop gained/lost, canonical splice site, and initiation codon variants, as well as missense variants predicted to be deleterious by either SIFT or PolyPhen-2 prediction tools and not detected homozygously) in our unrelated familial glioma patients was significantly higher (2 families with multiple variant carriers in 60 families, 3.33%) than in (1) Table 9 ). Because SNP rs498872 at 11q23 is one of the variants reported to specifically increase the risk for IDH1-mutant glioma [61] , we assessed this variant on germline DNA from tumor-affected members of families 1 and 2. While patient II.2 of family 1 diagnosed with prostate cancer was heterozygous for the risk allele (NM_015157.3:c.-199A>G), none of the patients affected by IDH1-mutant or IDH1-wild-type gliomas carried the risk allele ( Supplementary Fig. 2) . Therefore, the risk allele at 11q23 was not associated with the susceptibility for IDH1-mutant glioma in family 1.
Targeted ADAR and RNASEH2B sequencing was also performed on tumor DNA from all three tumor types found in patients carrying rare ADAR or RNASEH2B germline variants, i.e., IDH1-mutant gliomas of WHO grade II/III, glioblastomas (on geographically distinct test and validation cohorts), and prostate carcinomas (on geographically distinct test and validation cohorts). While no rare non-silent ADAR or RNASEH2B variants were found in 39 IDH1-mutant gliomas of WHO grade II/III, the allele frequency for the known AGS variant RNASEH2B,c.529G>A;p.(A177T) was 0.025 (1 in 40 alleles), i.e., 13 times higher, in a glioblastoma test cohort, and that of ADAR,c.577C>G;p.(P193A) was 0.00893 (1 in 112 alleles), i.e., 3 times higher, in a glioblastoma validation cohort compared to ExAC controls (0.00193 and 0.00298, respectively). In addition, three novel and one rare ADAR variant not previously associated with AGS were identified in the glioblastoma test and validation cohorts ( Supplementary  Tables 9, 10 ). The variants ADAR,c.577C>G;p.(P193A) and RNASEH2B,c.529G>A;p.(A177T), detected in one glioblastoma each, were also found in non-neoplastic tissue of the same patients (patient II.1 of family 3 and family 4), indicating that they are in fact germline alterations ( Fig. 1c, d; Supplementary Fig. 1c, d) . Furthermore, in addition to the RNASEH2B,c.529G>A;p. (A177T) variant in the glioblastoma of patient II.1 of family 4, the novel ADAR variant c.2891C>T;p.(A964V) was found, demonstrating that the tumor was simultaneously heterozygous for ADAR and RNASEH2B variants (Supplementary Table 10 ). Finally, we performed targeted sequencing of ADAR and RNASEH2B hotspot exons (see Materials and methods) in a test and a validation cohort of prostate carcinomas, to determine if our findings in glioblastoma also apply to prostate carcinoma. The allele frequency for ADAR,c.577C>G;p.(P193A) was 11 times higher in the prostate carcinoma test cohort (0.03333; 1 in 30 alleles) compared to ExAC controls (0.00298), whereas RNASEH2B,c.529G>A;p.(A177T) was 17 times higher in the test (0.03333; 1 in 30 alleles) and 5 times higher in the validation (0.01000; 1 in 100 alleles) cohort compared to ExAC controls (0.00193). In addition, the novel RNASEH2B variant c.608A>G;p. (D203G) was detected in one patient in the validation cohort (Supplementary Tables 9, 10 ). Again, the AGSassociated variants ADAR,c.577C>G;p.(P193A) and RNASEH2B,c.529G>A;p.(A177T) were germline alterations as indicated by their presence in DNA from nonneoplastic lymph node from the same patients ( Fig. 1e;  Supplementary Fig. 1e; Fig. 1f; Supplementary Fig. 1f ). All gliomas harboring ADAR and/or RNASEH2B variants had no co-deletion of chromosomal arms 1p and 19q (Supplementary Table 10 ), and were thus of astrocytic origin according to the current WHO classification of tumors of the central nervous system [40] .
In summary, we detect novel variants and increased allele frequencies of certain rare variants in the AGS-associated genes ADAR and RNASEH2B in the germline and tumors of glioma and prostate carcinoma patients, suggesting an association of ADAR and RNASEH2B alterations with glioma and prostate carcinoma risk and tumorigenesis, whereby germline variants in other genes may additionally contribute to tumor risk in these patients.
The ADAR p.(P193A) variant destabilizes the protein-Z-DNA complex resulting in a partial unbinding of the Z-DNA, and affects tumor cell proliferation
To gain insights into the effect of the ADAR p.(P193A) variant detected in the germline of glioma and prostate carcinoma patients at the molecular level, molecular dynamics simulations were carried out. Proline 193 is located in the Z-DNA/Z-RNA-binding domain (designated Zα) of ADAR, and is part of a β-hairpin motif (β-wing) directly involved in Z-DNA interaction. P193 mainly contributes to Z-DNA binding through hydrophobic interactions [64] . Therefore, using molecular dynamics simulations, a comparison of the structure and conformational dynamics of the Zα domain in wild-type and mutant ADAR together with the bound Z-DNA could be made. As compared to wild-type ADAR, the p.(P193A) variant significantly increased the flexibility of the protein, leading to large structural fluctuation, in particular of Z-DNA-binding elements, including helices α2 and α3, as well as the β-wing (β2 to β3) (Fig. 2a, b) . Along the molecular dynamics simulation, these fluctuations disturbed the well-defined Z-DNA-binding area and impaired shape complementarity resulting in an unbinding of the 3′ end of the Z-DNA and large conformational changes, thereby destabilizing the protein-Z-DNA complex (Fig. 2c, d) . Next, we aimed to determine whether the ADAR p.(P193A) variant might facilitate tumorigenesis by affecting proliferation. Human LN-229 glioma and human HCT116 colorectal cancer cells stably expressing either wild-type interferon-induced ADAR p150 protein or the ADAR p.(P193A) variant were generated ( Supplementary Fig. 3a) , and growth kinetics were determined. While expression of wild-type ADAR caused a reduced proliferation of tumor cells as compared to vector control, expression of the ADAR p.(P193A) variant did not result in this growth suppressive effect ( Supplementary Fig. 3b-g ). Our findings provide in silico and in vitro evidence that the ADAR p.(P193A) variant may play a role in tumorigenesis by impairing Z-DNA interaction and enhancing cell proliferation.
Detected rare RNASEH2B variants cause increased double-strand DNA damage and impair ribonucleotide excision repair
The RNase H2 complex is critical for the removal of ribonucleotides misincorporated into genomic DNA during replication and repair, and for the maintenance of genome integrity. MEFs from Rnaseh2b −/− mice display widespread genome instability, with γH2AX, a marker of DNA damage response to double-strand breaks, substantially increased [56] . We explored the ability of wild-type versus mutant Rnaseh2b to rescue this DNA damage phenotype.
Expression of the mutant murine proteins corresponding to the rare variants detected in glioma and prostate carcinoma patients, p.(K162N) and p.(A174T), in Rnaseh2b −/− MEFs ( Supplementary Fig. 4) showed significantly reduced rescue from DNA damage compared to wild-type Rnaseh2b (Fig. 3a) . Comparable results were obtained in patientderived human fibroblasts (Fig. 3b) . In comparison to fibroblasts from four controls, cells from patient II.2 of family 2, carrying the RNASEH2B,c.529G>A;p.(A177T) alteration, were characterized by a significantly higher number of nuclear γH2AX foci (Fig. 3b) . The observed DNA damage in RNase H2 deficient cells is generally thought to be the result of the impaired removal of misincorporated ribonucleotides. Consistent with this, we found that after expression of the Rnaseh2b p. (K162N) 
and p.(A174T) variants in Rnaseh2b
−/− MEFs, isolated genomic DNA was more sensitive to RNase HII digestion as compared to Rnaseh2b −/− MEFs rescued with wild-type Rnaseh2b (Fig. 3c, d ). This finding reflects a higher ribonucleotide content in the genomic DNA of Rnaseh2b −/− MEFs transfected with Rnaseh2b mutants versus wild-type Rnaseh2b. Our results suggest that the RNASEH2B germline variants identified in glioma and prostate carcinoma patients may promote tumorigenesis through increased double-strand DNA damage resulting from defective removal of genomeembedded ribonucleotides.
Patients with rare ADAR or RNASEH2B variants and their tumors recapitulate features of the AGS type I interferonopathy
Cerebral atrophy and leukoencephalopathy were described in over 90% of children with AGS commonly showing frontotemporal predominance [38] . Therefore, we evaluated tumor localization and neuroradiological findings in glioma patients carrying rare ADAR or RNASEH2B germline variants. All five gliomas were located in the frontal or temporal lobe (Supplementary Table 10 ), and one of four patients with available cranial magnetic resonance imaging showed bifrontal lobe atrophy (Fig. 4a) . Brain calcification is another classical hallmark of AGS [2, 38] . Therefore, we assessed the presence of calcifications in gliomas or non-neoplastic brain of patients carrying rare ADAR or RNASEH2B variants. Calcifications were detected in the tumor or non-neoplastic brain of all four glioma patients with ADAR or RNASEH2B germline variants analyzed histologically, whereby these were numerous or large in two of the four cases ( Supplementary Tables 10, 11 ; Fig. 4b, c ; Supplementary Fig. 5a, b) . Compared to five gliomas without ADAR or RNASEH2B variants, the six gliomas with ADAR or RNASEH2B variants showed an increased calcification score (Fig. 4d ). Calcifications were also significantly more frequent in prostate carcinomas with versus without ADAR or RNASEH2B variants (Supplementary Fig. 5c -e; Supplementary Table 11 ).
To test whether type I IFNs are upregulated in ADAR or RNASEH2B variant-positive gliomas comparable to the findings in the CSF of AGS patients [62, 63] , we determined the protein expression of interferon alpha 6 (IFNA6) by immunostaining of glioma sections. We observed that gliomas with ADAR or RNASEH2B variants showed a significantly higher IFNA6 expression in the cytoplasm of glial cells as compared to gliomas without ADAR or RNASEH2B variants ( Fig. 4e-h; Supplementary Fig. 6 ; Supplementary  Table 11 ). Previously, it was reported that the type I IFNinducible chemokine CXCL10 was elevated in the CSF and plasma of AGS patients [57, 62, 63] , and in skin lesions from patients with systemic lupus erythematosus (SLE) carrying heterozygous RNASEH2B variants [23] . Therefore, we performed CXCL10 immunostaining on tissue sections from gliomas with and without ADAR or RNASEH2B variants. Whereas ADAR or RNASEH2B variant-negative gliomas had a low mean CXCL10 score, gliomas with ADAR or RNASEH2B variants showed significantly enhanced CXCL10 expression in glial cells ( Fig. 4i-l ; Supplementary Fig. 6; Supplementary Table 11 ). Increased IFNA6 and CXCL10 expression was paralleled by a significantly higher CD68 expression in gliomas with versus without ADAR or RNASEH2B variants, consistent with an enhanced, IFNA6/ CXCL10-induced recruitment of macrophages and microglial cells into ADAR or RNASEH2B variant-positive tumors (Supplementary Fig. 7; Supplementary Table 11 ). −/− MEFs with more than five γH2AX DNA damage foci, than after wild-type Rnaseh2b re-expression (mean ± SD for n = 4 independent experiments). b In human fibroblasts from patient II.2 of family 2 carrying the RNASEH2B,c.529G>A;p.(A177T) variant, significantly more nuclei harbored 1-3 γH2AX foci as compared to four control fibroblast cell lines, indicating increased double-strand DNA damage (mean ± SD for n = 3 independent experiments). Representative images of stained fibroblast nuclei are shown. c Genomic DNA from Rnaseh2b +/+ MEFs, Rnaseh2b +/− MEFs, and transiently transfected Rnaseh2b −/− MEFs was analyzed on an alkaline agarose gel to estimate sensitivity to recombinant RNase HII enzyme as a measure of ribonucleotide excision repair and DNA integrity. d Densitometric evaluation of high-molecular-weight genomic DNA bands from c revealed a decreased rescue of Rnaseh2b −/− genomic RNase HII-mediated DNA fragmentation reflecting a higher ribonucleotide content when expressing Rnaseh2b mutants versus wildtype (mean ± SD for n = 3 independent experiments). *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001 (Student's t test)
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AGS has also been associated with increased expression of ISG transcripts in peripheral blood [15, 60] . Therefore, we assessed the expression of six genes significantly upregulated in AGS patients with biallelic ADAR mutations, i.e., IFI27, IFI44L, IFIT1, ISG15, RSAD2, and SIGLEC1 [60] , in whole blood from three glioma patients carrying AGSassociated ADAR or RNASEH2B germline mutations. Transcript levels of IFI27, IFIT1, and RSAD2 were significantly increased in peripheral blood of these glioma patients as compared to 20 controls matching the patients in gender and age, while IFI44L, ISG15, and SIGLEC1 mRNA levels did not differ in glioma patients and controls ( Fig. 4m ; Supplementary Fig. 8 ).
Our findings indicate that the detected germline or somatic variants in both ADAR and RNASEH2B are associated with features of the AGS type I interferonopathy in glioma and prostate carcinoma tissue as well as in patients affected by these tumors. More specifically, our results provide in vivo evidence that these variants lead to upregulation of IFN as well as IFN-induced genes, and suggest that they may contribute to tumorigenesis via enhanced interferon type I signaling. Supplementary Tables 10, 11 , and shown in Supplementary Fig. 5 . The calcification score was elevated in gliomas with (n = 6) versus without (n = 5) rare ADAR or RNASEH2B variants (mean ± SD) (d). e-h IFNA6 immunoreactivity in a representative glioma without ADAR or RNASEH2B variants (e: tumor Gb6) and two representative gliomas with ADAR or RNASEH2B variants (f: tumor Gb9; g: glioma from patient III.2 of family 1); scale bar 60 µm. The IFNA6 expression was significantly higher in gliomas with (n = 6) versus without (n = 5) ADAR or RNASEH2B variants (mean ± SD) (h). i-l Immunostaining of type I IFN-inducible CXCL10 in a representative glioma without ADAR or RNASEH2B variants (i: tumor Gb19) and two representative gliomas with ADAR or RNASEH2B variants (j: glioma from patient III.3 of family 1; k: tumor Gb16); scale bar 60 µm. Gliomas with ADAR or RNASEH2B variants (n = 6) showed significantly higher CXCL10 scores as compared to gliomas without ADAR or RNASEH2B variants (n = 5) (mean ± SD) (l). m Glioma patients with rare ADAR or RNASEH2B germline variants (filled black symbols; n = 3) show significantly increased transcript levels of ISGs IFI27 (circles), IFIT1 (squares), and RSAD2 (triangles) in whole blood normalized to 18S expression levels versus controls (unfilled symbols; n = 20). Scatter plots show RQ values on a log 10 scale for each individual (mean for n = 2 independent experiments performed in triplicate, red lines indicate the mean value of each group). Given are significance levels calculated using two-tailed Student's t test. The expression differences between patients and controls remain significant after correcting for multiple testing [6] . WT, wild-type ADAR and RNASEH2B; mut, mutant ADAR and/or RNASEH2B; pts, patients; *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001 (Student's t test) Enhanced ISG expression in vitro due to rare ADAR and RNASEH2B variants can be blocked by janus kinase (JAK) 1/2 inhibitor Ruxolitinib To confirm that the increase of ISG transcripts detected in the peripheral blood of glioma patients is due to ADAR and RNASEH2B variants, LN-229 cells were transiently transfected with wild-type or mutant ADAR or RNASEH2B constructs ( Supplementary Fig. 9 ), and IFI27, IFIT1, and RSAD2 mRNA levels were quantified. Expression of IFI27, IFIT1, and RSAD2 was significantly higher in tumor cells expressing ADAR p.(P193A) as well as RNASEH2B p. (K165N) and RNASEH2B p.(A177T) mutants as compared to wild-type ADAR or RNASEH2B, indicating an IFN type I response (Fig. 5a) .
With the aim to identify therapeutic or prophylactic compounds for individuals carrying pathogenic ADAR or RNASEH2B variants, we used this cellular model to study signaling pathways involved in ADAR and RNASEH2B-mediated induction of ISG expression. It has been proposed that ADAR inactivation induces a type I IFN response and enhanced ISG expression via phosphorylation and subsequent nuclear translocation of transcription factor IRF3 [49] . Therefore, we compared nuclear IRF3 accumulation indicative of pIRF3 levels between LN-229 cells expressing wildtype or mutant ADAR or RNASEH2B. Immunofluorescence revealed that a significantly higher percentage of cells had an elevated nuclear IRF3 score indicating increased levels of transcriptionally active IRF3 upon transient expression of mutant compared to wild-type ADAR and RNASEH2B ( Fig. 5b, c; Supplementary Fig. 10 ). Our results suggest that the elevated ISG expression seen with mutant ADAR and RNASEH2B involves activation and nuclear translocation of IRF3.
Recently, constitutive epidermal growth factor receptor (EGFR) signaling was shown to activate IRF3 leading to increased expression of IFI27 and IFIT1 via the JAK/ STAT1/2 pathway, which could be blocked by the JAK inhibitor Ruxolitinib in glioblastoma cell lines [10] . Therefore, we explored whether Ruxolitinib would have the same effect on high ISG expression induced by mutant ADAR or RNASEH2B in glioblastoma cells, in which we had shown IRF3 activation. We incubated LN-229 cells expressing wild-type or mutant ADAR or RNASEH2B with Ruxolitinib, and expression of IFI27, IFIT1, and RSAD2 was quantified. Ruxolitinib treatment was found to abrogate the elevated ISG transcription levels seen for mutant ADAR and RNASEH2B (Fig. 5d) . In summary, glioblastoma cells expressing mutant ADAR or RNASEH2B show a type I IFN response via activation of IRF3 that can be blocked by the JAK inhibitor Ruxolitinib, indicating that JAK/STAT signaling is involved. Our results suggest that glioma patients carrying germline mutations in ADAR or RNASEH2B might benefit from JAK inhibitors such as Ruxolitinib for the treatment of a glioma or prostate carcinoma or as an agent for tumor prevention.
Discussion
Here, we provide data suggesting that rare ADAR and RNASEH2B variants are associated with glioma and prostate carcinoma risk and tumorigenesis as well as a type I interferon signature. The starting point of this study was family 1 with a clinically presumed susceptibility for glioma and prostate carcinoma because of four affected individuals in three consecutive generations. By whole-exome sequencing, three family members affected by IDH1-mutant anaplastic gliomas or prostate carcinoma were found to be simultaneously heterozygous for rare germline variants in ADAR and RNASEH2B, while three unaffected family members were not. Previously, homozygous or compound heterozygous mutations of ADAR and RNASEH2B have been reported to cause AGS [17, 60] , whereby the ADAR c.577C>G;p. (P193A) variant detected here in German cancer family 1 and found to be enriched 3-to 11-fold in the germline and tumor DNA of glioblastoma and prostate carcinoma test and/ or validation cohorts as compared to ExAC controls, has been described in five AGS families of European ancestry [60] . This alteration lies in the Zα domain of the adenosine deaminase, which specifically recognizes DNA and RNA in a higher energy Z-conformation, and only affects the IFNinducible p150 isoform of ADAR. Here, molecular dynamics simulations indicate an increased structural flexibility of the ADAR Zα domain due to the p.(P193A) variant, which significantly affected the Z-DNA/Z-RNA-binding area, impairing Z-DNA interaction and destabilizing the protein-Z-DNA complex. Our findings are consistent with the previous results that binding of Z-DNA to the ADAR Zα domain is shape-specific [24, 29, 64] . Moreover, our simulations may have identified the structural basis underlying both the altered RNA editing activity described previously [44] and the impaired growth suppression of the ADAR p.(P193A) variant shown here, as compared to the growth suppressive effect of wild-type ADAR reported here and previously [50] . Both effects may be linked, since changes of RNA editing levels may be a general mechanism to promote tumor growth [66] . Furthermore, localization of the ADAR p.(P193A) variant to cytoplasmic stress granules, which requires a functional Zα domain [47] , may be impaired.
In addition to the novel RNASEH2B variant in family 1, we detected the RNASEH2B c.529G>A;p.(A177T) alteration, previously reported in 14 of 18 AGS families of European or North-African descent [17] , in the glioblastoma patient of German cancer family 2 resulting in a significantly higher frequency of rare deleterious RNASEH2B variants in the germline of familial glioma patients than in ExAC controls. As shown in Rnaseh2b −/− MEFs, both Rnaseh2b variants impact on ribonucleotide excision repair and DNA damage. In addition, fibroblasts from our glioblastoma patient carrying the RNASEH2B c.529G>A;p.(A177T) alteration showed signs of chronic low-level DNA damage, as described previously for fibroblasts with a heterozygous RNASEH2B mutation from an SLE patient [23] . That report demonstrates a significant contribution of rare variants of the RNASEH2 genes, RNASEH2A, RNASEH2B, and RNASEH2C, to SLE risk [23] . Taken together, the study by Günther et al. and our report extend the phenotypic spectrum caused by ADAR and RNASEH2B genetic variation beyond AGS to SLE and glioma and prostate carcinoma risk. This link is not unexpected, because SLE patients have an overall increased risk of malignancy compared with the general population [22] . A direct association between AGS genes and other cancer types was suggested by two recent studies [14, 51] . Clifford and colleagues reported on a homozygous germline SAMHD1 mutation in an AGS patient who developed CLL at 24 years of age, and acquired SAMHD1 mutations in around 10% of relapsed/refractory CLL patients [14] . Studying over 10,000 cases and over 20,000 controls, Permuth and colleagues found a significant association between genetic variation in ADAR and epithelial ovarian cancer susceptibility [51] .
Our study provides evidence that rare variants in both AGS genes found altered here, ADAR and RNASEH2B, are associated with features of the AGS type I interferonopathy in tumors and tumor patients, whereby the patients were not affected by the full spectrum of AGS symptoms, because they were heterozygous or simultaneously heterozygous mutation carriers. First, seven of eight gliomas with an ADAR or RNASEH2B variant were located in the frontotemporal brain, where AGS-associated leukoencephalopathy is predominant [38] . Second, calcification, an AGS hallmark usually occurring in the brain [2, 38] , was more likely in gliomas and significantly more pronounced in prostate carcinomas with ADAR or RNASEH2B variants than without. Third, expression of IFNA and type I IFN-inducible CXCL10, produced by astrocytes in AGS [63] , was elevated in gliomas with ADAR and RNASEH2B variants compared to ADAR and RNASEH2B wild-type gliomas. Similarly, high CXCL10 expression was previously observed in lesional skin from an SLE patient carrying a heterozygous RNASEH2B variant [23] . Fourth, similar to AGS patients and their heterozygous parents [15, 60] , increased expression of a subset of ISG transcripts (IFI27, IFIT1 and RSAD2) was found in peripheral blood of glioma patients carrying germline ADAR and/ or RNASEH2B variants.
The link between ADAR and RNASEH2B variants and enhanced expression of certain ISGs was corroborated by our finding that elevated levels of IFI27, IFIT1, and RSAD2 could also be induced in vitro by expressing ADAR and RNASEH2B variants in tumor cells. Using this cellular model, we found that stimulation of ISG expression by ADAR and RNASEH2B variants is mediated by activation of the transcription factor IRF3, known to play a key role in antiviral innate immunity. It was recently shown that IRF3 is also activated by constitutive EGFR signaling leading to expression of IFI27 and IFIT1 in glioblastomas [10] . Aberrant EGFR signaling caused by EGFR amplification and/or constitutively activating mutation is common in human tumors including malignant astrocytic gliomas and prostate carcinomas [3, 11] , and enhances tumorigenicity [33] . Here, we propose that germline or somatic ADAR and RNASEH2B variants result in the same downstream signals as constitutively active EGFR, thus representing an alternative mechanism for tumorigenesis in certain cancers such as gliomas and prostate carcinomas, whereby tumor initiation is enhanced by ADAR and RNASEH2B germline variants as opposed to malignant progression by somatic deregulation of EGFR signaling. IFN pathway activation by constitutive EGFR signaling via IRF3 was abolished by JAK inhibitor Ruxolitinib [10] , as might be expected, because IRF3 activates the JAK-STAT pathway by stimulating IFN-β transcription leading to the transcription of ISGs. Here, we show that Ruxolitinib also suppresses ADAR and RNASEH2B variant-mediated expression of the ISGs IFI27 and IFIT1. Thus, targeting the JAK-STAT pathway by inhibitors may have prophylactic or therapeutic potential in individuals carrying pathogenic ADAR and RNASEH2B variants regarding the tumor phenotype. Previous studies have indicated that the JAK2 inhibitor AZD1480 suppresses the growth of human xenografts from prostate cancer cells [28] , and from glioma cells, thus increasing the survival of mice bearing intracranial glioblastoma xenografts [45] , supporting the development of JAK inhibitors for the treatment and possibly the prevention of solid tumors in individuals with ADAR and RNASEH2B variants. We propose that rare ADAR and RNASEH2B germline variants specifically increase the risk for diffusely infiltrating gliomas without co-deletion of chromosomal arms 1p and 19q, which may, however, carry IDH1 mutations or not. According to the current WHO classification of tumors of the central nervous system, diffuse gliomas without 1p/19q deletion are astrocytic tumors [40] . Furthermore, the IDH mutation status is a major classification parameter for gliomas [40] . Our data suggest that in the brain, rare ADAR and RNASEH2B germline variants lead to astrocytic tumors only, which may then acquire IDH1 mutations or not. From a transgenic mouse with CNS expression of IFNA, we know that the neuropathologic changes include astrocyte hypertrophy, progressive calcification, and upregulation of a number of IFNA-regulated genes [8] , mimicking the findings in the diffuse astrocytic tumors with rare ADAR and RNASEH2B variants described here. Therefore, the type I interferonopathy in patients carrying rare ADAR and RNASEH2B germline variants may specifically impact astrocytes or astroglial progenitors in the brain, thereby increasing the risk for the development of astrocytic gliomas. Recently, astrocytes were shown to produce IFNA as a paracrine signal that supports metastatic tumor growth, providing evidence for an association between inflammatory cytokines, such as IFNA, and growth of brain metastatic cells [12] . Mediated by dsDNA, metastatic cancer cells triggered astrocyte cytokine release via cGAS by transferring cGAMP through gap junctions into neighboring astrocytes, where IRF3 was activated via STING [12] . A role for the IFN stimulator STING in the control of cancer was shown in STING −/− mice, which were largely resistant to skin carcinogenesis induced by a mutagen causing accumulation of nuclear DNA in the cytosol, a trigger leading to intrinsic cytokine production and tumor development in a STING wild-type setting [1] . The cGAS/ STING nucleic acid-sensing pathway is also relevant to AGS as reported in Rnaseh2b G37S/G37S and Rnaseh2b
A174T/A174T
knock-in mice [42, 53] . Therefore, data from this and other studies provide direct and indirect evidence for an association between AGS-related gene mutations and type I IFNinduced tumorigenesis, whereas the study of cancer risk in patients with AGS is hampered by the fact that the severe neurological dysfunction often causes lethality in childhood, with only around 2% of patients still alive at more than 30 years of age [15] . IDH1 is another gene, for which an association between somatic mutation, inflammation, and glioma tumorigenesis is proposed, whereby the starting point is the formation of the oncometabolite 2-hydroxyglutarate leading to overexcitation of NMDA receptors, increased IL-1β production, and IL-6 induction via the JAK/STAT pathway [46] . In the gliomas with somatic IDH1 mutations of our study, the germline ADAR and/or RNASEH2B variants will have preceded this mutation, while in the tumor cells, variation in all three genes may additively promote inflammation and drive tumor progression. However, since IDH1 mutations were not detected in most gliomas with ADAR and/or RNASEH2B variants described here, ADAR and RNASEH2B variants may represent genetic equivalents of IDH1 mutations in inducing inflammation-driven malignant transformation.
In summary, our results link ADAR and RNASEH2B, previously associated with the inflammatory disease AGS and the autoimmune disorder SLE, and an enhanced type I IFN response to glioma and prostate carcinoma risk and tumorigenesis. Furthermore, we propose that targeting the type I IFN signaling axis by inhibitors may have prophylactic or therapeutic potential regarding a tumor phenotype in individuals carrying pathogenic ADAR and RNASEH2B variants.
